caa a22 4500 465739059 CHVBK 20180323111803.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF02244603 doi (NATIONALLICENCE)springer-10.1007/BF02244603 Effects of m -chlorophenylpiperazine in normal subjects: a dose-response study [Elektronische Daten] [R. Kahn, S. Wetzler, G. Asnis, M. Kling, R. Suckow, H. van Praag] m-Chlorophenylpiperazine (MCPP), a direct 5HT receptor agonist, was administered orally to 20 normal subjects in two doses (0.25 and 0.5 mg/kg) in a placebo-controlled design. Behavioral responses; ACTH, cortisol, prolactin and MCPP blood level; temperature and pulse rate were measured over a 210-min period after administration of tablets. Non-linear dose-response relationships between MCPP and ACTH, cortisol and prolactin response were found. On the higher dose, a significant increase in the number of physical symptoms was also noted and three subjects (15%) had a panic attack, while one subject (5%) had a panic attack on the lower dose. No effects on other behavioral variables, pulse rate and temperature were found using either dose. These findings attest to the usefulness of MCPP as a challenge agent to assess 5HT receptor hypersensitivity when given at a low oral dose (i.e. around 0.25 mg/kg), and to assess 5HT receptor hyposensitivity when given at higher oral doses (i.e. around 0.5 mg/kg). Springer-Verlag, 1990 m -Chlorophenylpiperazine nationallicence Serotonin nationallicence Dose-response nationallicence Normal subjects nationallicence Kahn R. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut Wetzler S. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut Asnis G. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut Kling M. Clinical Neuroendocrinology Branch, NIMH/DIRP, 20892, Bethesda, MD, USA aut Suckow R. Analytical Psychopharmacology Laboratory, New York State Psychiatric Institute, 10032, New York, NY, USA aut van Praag H. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut Psychopharmacology Springer-Verlag 100/3(1990-03-01), 339-344 0033-3158 100:3<339 1990 100 213 https://doi.org/10.1007/BF02244603 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244603 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kahn R. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut NATIONALLICENCE 700 1- Wetzler S. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut NATIONALLICENCE 700 1- Asnis G. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut NATIONALLICENCE 700 1- Kling M. Clinical Neuroendocrinology Branch, NIMH/DIRP, 20892, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Suckow R. Analytical Psychopharmacology Laboratory, New York State Psychiatric Institute, 10032, New York, NY, USA aut NATIONALLICENCE 700 1- van Praag H. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 10467, New York, NY, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 100/3(1990-03-01), 339-344 0033-3158 100:3<339 1990 100 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer